Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Sumito Shingaki
Use of Eribulin as an Earlier-Line Chemotherapy for Patients With HER2-negative Metastatic Breast Cancer
Journal of Cancer
Oncology
Related publications
Outcome of Eribulin as a Late Treatment Line for Thai Metastatic Breast Cancer Patients
OncoTargets and Therapy
Oncology
Pharmacology
Capecitabine and Vinorelbine as an All-Oral Chemotherapy in HER2-Negative Locally Advanced and Metastatic Breast Cancer
Breast Care
Surgery
Oncology
Assessing the Tolerability and Efficacy of First-Line Chemotherapy in Elderly Patients With Metastatic HER2−ve Breast Cancer
ecancermedicalscience
Cancer Research
Oncology
Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer
New England Journal of Medicine
Medicine
Capecitabine in Combination With Docetaxel in First Line in HER2-Negative Metastatic Breast Cancer: An Observational Study
Pathology and Oncology Research
Medicine
Forensic Medicine
Pathology
Oncology
Cancer Research
Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate With Trastuzumab as First-Line Therapy for Locally Recurrent or Metastatic HER2-Positive Breast Cancer
Clinical Breast Cancer
Cancer Research
Oncology
Eribulin Suppresses New Metastases in Patients With Metastatic Breast Cancer
In Vivo
Biochemistry
Medicine
Genetics
Pharmacology
Molecular Biology
Capecitabine and Irinotecan as First- Line Chemotherapy for Patients With Metastatic Colorectal Cancer
Journal of IMAB - Annual Proceeding (Scientific Papers)
Dentistry
Prognostic Impact of ANX7-GTPase in Metastatic and HER2-Negative Breast Cancer Patients
Clinical Cancer Research
Cancer Research
Oncology
